Selective thromboxane inhibition: a new approach to antiplatelet therapy.
Antiplatelet drugs as exemplified by aspirin are used frequently to prevent stroke. Aspirin inhibits the formation of both the potent platelet aggregator, thromboxane A2 and the potent anti-aggregator, prostacyclin. Another approach to the inhibition of platelet aggregation might involve selective suppression of thromboxane formation. We report our experience in swine with UK-38,485, a drug which selectively inhibits thromboxane formation. The rationale and potential uses of UK-38,485 in the in vivo prevention of platelet aggregation and for the therapy of cerebrovascular disease are discussed.
D000818:Animals; D002561:Cerebrovascular Disorders / Q000188:drug therapy; D007093:Imidazoles / Q000627:therapeutic use*; D008297:Male; D010974:Platelet Aggregation / Q000187:drug effects*; D013552:Swine; D013929:Thromboxane B2 / Q000096:biosynthesis / Q000097:blood; D013931:Thromboxanes / Q000037:antagonists & inhibitors*
D007093:Imidazoles; D013931:Thromboxanes; C039242:dazmegrel; D013929:Thromboxane B2